Polyglutamine spinocerebellar ataxias — from genes to potential treatments
Henry L. Paulson,Vikram G. Shakkottai,H. Brent Clark,Harry T. Orr
DOI: https://doi.org/10.1038/nrn.2017.92
IF: 38.755
2017-08-17
Nature Reviews Neuroscience
Abstract:Key PointsAmong the diverse group of dominantly inherited spinocerebellar ataxias (SCAs), those attributable to the expansion of polyglutamine (polyQ)-encoding CAG repeats include the most prevalent and severe forms (SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17).The polyQ SCAs typically present with gait ataxia, limb incoordination, speech disturbance and oculomotor abnormalities, and death is caused by brainstem failure; however, SCA7 is uniquely characterized by retinal degeneration, and SCA6 is usually a pure cerebellar disease that does not reduce lifespan.In the polyQ SCAs, the Purkinje cells of the cerebellar cortex are a prominent pathological target. An exception is SCA3, in which Purkinje cells are less involved.Changes in the expression of receptors and ion channels important for regulating membrane excitability contribute to motor dysfunction, as well as to structural changes in neurons that lead to cell death and thus may be targets for the treatment of motor dysfunction.The diverse biological functions of the polyQ SCA proteins, which include regulation of transcription, RNA splicing and metabolism, and deubiquitinase activity, help to specify the disease pathogenesis of each disease.Several cellular pathways are implicated in the pathogenesis of each polyQ SCA; hence, developing therapies that directly target the expression of the mutant gene or protein is a major current focus of research in this field.
neurosciences